GA29102: Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared with Placebo in Patients with Moderate to Severe Active Ulcerative Colitis who are Naïve to TNF Inhibitors
August 15, 2014
Gastroenterology - Stomach
Principal Investigator: Nirmal Kaur, MD
Purpose of Research: The purpose of this research study is to determine whether etrolizumab is a safe and effective treatment for ulcerative colitis in patients with moderate-to severe- active ulcerative colitis who have previously been unsuccessfully treated with immunosuppressants such as azathioprine, 6-mercaptopurine, and methotrexate.
Please contact us for a full list of criteria.